General objective: to determine the factors among cancer patients who developed immune checkpoint inhibitor associated acute kidney injury (ICI AKI) such as clinico-demographic profile of patients receiving immune checkpoint inhibitors including age, sex, cancer type, functional status, comorbidities, body mass index (BMI), chemotherapy use, and medications that may cause nephrotoxicity. Specific objective: to determine the incidence of acute kidney injury and immune checkpoint inhibitor associated acute kidney injury, electrolyte and urine abnormalities, clinical outcomes, and progression to chronic kidney disease among patients treated with immune checkpoint inhibitor This was a single-center retrospective cohort study of cancer patients receiving ICI between January 2018 and December 2024 at St. Luke’s Medical Center Quezon City. To be included, patients must have cancer, at least 18 years old, and had to receive ≥ 1 dose of ICI. They were excluded if they are already on renal replacement therapy (RRT), no baseline serum creatinine (sCr) prior to giving the first dose of ICI, or sCr after the 1st dose or ≥ 3 months after administration of ICI. Among the 210 patients who were treated with ICI, 8(3.8%) developed ICI AKI. 37.5% progressed to CKD among patients with ICI AKI. Univariate and Multivariate analysis were done to identify the risk factors associated with ICI AKI. Use of NSAID showed to increase the incidence of ICI AKI among patients receiving ICI. Urinalysis showed that 83 (39.52%) patients had hematuria while 94(44.76%) had proteinuria. 72 (34.3%) patients had electrolyte abnormalities. The most common electrolyte abnormality was hyponatremia (25.7%). NSAID use was associated with increased risk of development of ICI AKI. The most common electrolyte abnormality was hyponatremia. 30 patients developed AKI with 8 patients developing ICI AKI. Among patients who developed ICI AKI, 37.5% progressed to CKD. 5 out of 8 patients who developed ICI AKI had CKD.